SynthesisEye (London, England)2026
Functional visual loss: a systematic review and meta-analysis of epidemiology, prognosis and treatment.
Synthesis in Eye (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Functional visual loss is a common issue in neuro-ophthalmology settings. There are many studies focused on diagnosis, but there is limited literature on associated epidemiology, phenomenology, prognosis and treatment. We carried out the first systematic review and meta-analysis assessing these domains. We systematically reviewed PubMed from 1951 for studies reporting clinical data on adults and children with functional visual loss. Data on variables relevant to epidemiology, phenomenology, comorbidity, risk factors, prognosis and treatment were extracted. Random effects meta-analyses were performed where appropriate. Forty-four studies of functional visual loss (n = 2284, 67% female) were included. The pooled median age was 43 years (IQR 12.5-43 years). Common associations included facial/ocular trauma (19%, n = 288), ocular comorbidity (25%, n = 470), headache (39%, n = 124) and other functional symptom/disorder (10-29%). Good quality data on psychiatric comorbidity and adverse childhood experience were unavailable. Prognosis data (n = 1019, 13 studies) were heterogeneous, but outcome appeared more favourable in paediatric studies. Most studies did not distinguish between symptomatic visual loss and functional visual signs which are asymptomatic (such as spiralled fields) or disproportionate to symptoms (such as severe acuity loss in someone with minor visual symptoms). There are very limited data on treatment. This systematic review highlights some basic epidemiological data and relevant aetiological factors in functional visual loss but also the significant gaps that must be addressed to improve care for this disabling condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.